Biotech Pest Management

biotechpestmanagement.com

Biotech Pest Management is a Charleston, South Carolina exterminator specializing in pest control services for residential and commercial property; including bed bug, mosquito and wildlife management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

news image

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

news image

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More

Cell and Gene Therapy

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

news image

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More

MedTech, Medical

MAGENTA TO EXPLORE STRATEGIC OPTIONS AND MAXIMIZE SHAREHOLDER VALUE

Magenta Therapeutics | February 03, 2023

news image

On February 2, 2023, Magenta Therapeutics, a clinical-stage biotech firm focused on enhancing stem cell transplantation, announced that it has completed a business evaluation, including a review of its programs, resources, and capabilities. Magenta has decided to cease further program development and conduct a complete examination of strategic alternatives aimed at maximizing shareholder value. Magenta will investigate potential strategic options, including, but not limited to, ...

Read More
news image

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More
news image

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More
news image

Cell and Gene Therapy

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More
news image

MedTech, Medical

MAGENTA TO EXPLORE STRATEGIC OPTIONS AND MAXIMIZE SHAREHOLDER VALUE

Magenta Therapeutics | February 03, 2023

On February 2, 2023, Magenta Therapeutics, a clinical-stage biotech firm focused on enhancing stem cell transplantation, announced that it has completed a business evaluation, including a review of its programs, resources, and capabilities. Magenta has decided to cease further program development and conduct a complete examination of strategic alternatives aimed at maximizing shareholder value. Magenta will investigate potential strategic options, including, but not limited to, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us